预约演示

更新于：2026-09-08

rVSV-ZEBOV

更新于：2026-09-08

概要

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live)、Ebola Zaire Vaccine, Live、recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein

+ [11]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染其他疾病

在研适应症

埃博拉病毒性疾病

非在研适应症-

原研机构

Public Health Agency of Canada

在研机构

Merck Canada, Inc.

Merck Sharp & Dohme (UK) Ltd.Merck Sharp & Dohme BV

+ [1]

非在研机构

NewLink Genetics Corp.

Merck Sharp & Dohme Corp.

Canadian Institutes of Health Research

权益机构

MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.

NewLink Genetics Corp.

Merck & Co., Inc.

最高研发阶段批准上市

首次获批日期

欧盟 (2019-11-11),

埃博拉病毒性疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

项与 rVSV-ZEBOV 相关的临床试验

NCT05202288

/ Not yet recruiting临床2期IIT

Phase IIa, Randomized, Open-label, Parallel-group Trial to Assess the Immunogenicity, Safety and Tolerability of Ervebo Vaccine Administered With Inmazeb to Healthy Adult Volunteers.

Ebola virus disease (EVD) is emerging regularly in various African countries for various reasons: during contact with mortal remains, during an unsafe burial or following the viral dissemination around a recovered patient.
However, tools to fight the spread of the disease are being made available to countries affected by EVD. A vaccine (Ervebo), developed by the Merck laboratory, demonstrated its efficacy in protecting contacts and contacts of contacts in the "Ebola That's Enough" trial and two monoclonal antibodies (Mabs) have demonstrated their efficacy in reducing mortality in patients with EVD: REGN-E3B (Inmazeb) and Mab114 (Ebanga).
The question of their use in post-exposure prophylaxis (PEP), defined as the treatment of contacts at very high risk of contracting EVD, is essential. Vaccination with Ervebo does not appear to be a good standalone option for PEP, particularly because antibody synthesis is delayed, and the vaccine is likely to be inactive for 10 days after administration. Monoclonal antibodies, on the other hand, seem to be a promising avenue in this indication because of their rapid action on the inhibition of virus entry into the cell.
Moreover, Ervebo vaccine expresses the viral target recognized by mAbs, GP EBOV. It is therefore possible that the vaccine response (production of vaccine antibodies) is inhibited by mAbs, which bind to GP EBOV and prevent vaccine replication, particularly in the case of concomitant administration.
However, no data on vaccine efficacy in combination are available. The question of the interaction between the monoclonal antibody and Ervebo and the delay between the administration of these two strategies remains unresolved.
The hypothesis of this trial is that Ervebo vaccine efficacy is diminished with the concomitant administration of a monoclonal antibody, especially if this administration is close (short time between Mabs and vaccination). We hypothesize that with an optimal delay between Mabs and vaccination, the immunogenicity of the vaccine when administered with monoclonal antibodies could be non-inferior to the vaccine alone, thus providing optimal short and long term protection.
The main objective of this study is to evaluate the extent of effect, if any, of Inmazeb administration on vaccine-induced neutralizing antibody responses to Zaire Ebola virus by Ervebo vaccine. If an interaction is observed, this will possibly enable determination of the time interval required between the administration of Inmazeb and Ervebo vaccine.
The trial will have 6 arms. A control arm of vaccination alone will serve to characterize the immune response to the vaccine and it will be used as a comparator of vaccine immune response in the intervention arms. A control arm of mAb alone will serve to characterize the pharmacokinetic profile of mAb in the Guinean population. The 4 arms including different doses of Inmazeb plus vaccination were designed to mimic a time interval between Ervebo and Inmazeb administration (15, 57 and 169 days after Inmazeb).

开始日期2027-01-01

申办/合作机构

France Recherche Nord & Sud SIDA HIV-Hepatites

[+5]

NCT06841614

/ Not yet recruiting临床3期IIT

Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts at High Risk of Developing Ebola Virus Disease (EVD)

EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.
The trial will be open during EVD epidemics and will recruit asymptomatic participants at high risk of developing EVD.
Participants will be randomized (1:1) into one of two trial arms:
* Arm 1 (ERV): Ervebo D0 (72 million PFU IM)
* Arm 2 (ERV+IMZ): Ervebo D0 (72 million PFU IM) + Inmazeb IV (150 mg/kg) D0 + Ervebo D56 (revaccination)
Definition of high-risk:
Direct contact with a person with EBOV PCR-confirmed EVD with diarrhea, vomiting or external bleeding ("wet symptoms"), or with their body fluids; Direct contact with the dead body of a person with confirmed or probable EVD; Needlestick with a syringe contaminated by the blood of a person with confirmed or probable EVD; Or a child born to or breastfed by an individual with EVD
Trial follow-up All participants are monitored daily for a minimum of 21 days.
Some visits are conducted in person at the investigation site, also called the Post-Exposure Prophylaxis (PEP) center:
* at Day 5, Day 10, and Day 21 for the ERV arm,
* at Day 5, Day 10, Day 21, and Day 56 for the ERV+IMZ arm. Other visits are conducted at home or by phone, in collaboration with the Ministry of Health's surveillance team.
Participants in the ERV+IMZ arm have an in-person visit at Day 56 to be revaccinated with the Ervebo vaccine to compensate for potential inhibition of the vaccine response when Ervebo is administered simultaneously with Inmazeb.
Participants in the ERV arm have a phone visit at Day 56. For all participants, a phone visit is scheduled at Day 60. It corresponds to the last visit for all trial participants.
Follow-up in Case of Hospitalisation In case of clinical signs suggestive of EVD, participants enter the suspected case management pathway at the Ebola Treatment Center (ETC).
If EVD is confirmed by EBOV PCR, participants are allowed at the ETC, and their study samples are discontinued. They continue to be followed by the research team, and daily data are collected throughout their stay at the ETC until they are discharged alive or deceased. The day of discharge from the ETC marks the end of follow-up in the study for these participants.
Of note, participants in the ERV+IMZ arm who have confirmed EVD are not revaccinated at day 56.
Of note, participants in the ERV+IMZ arm who have confirmed EVD are not revaccinated at day 56.
If EVD is not confirmed, participants continue to be followed up by the PEP center according to the protocol.

开始日期2026-09-01

申办/合作机构

ANRS Emerging infectious diseases

[+4]

NCT05959421

/ Withdrawn临床3期IIT

Durability of Immunity Induced by the Ebolavirus Vaccine VSV-EBOV and As-sessment of a Booster Dose for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebolavirus Exposure

This study is a multi-center, open label, randomized phase 3b trial to assess the durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV ( with or without booster vaccination) in individuals at potential occupational risk for ebolavirus exposure

开始日期2026-06-01

申办/合作机构

Universitätsklinikum Hamburg-Eppendorf

[+3]

100 项与 rVSV-ZEBOV 相关的临床结果

登录后查看更多信息

100 项与 rVSV-ZEBOV 相关的转化医学

登录后查看更多信息

100 项与 rVSV-ZEBOV 相关的专利（医药）

登录后查看更多信息

155

项与 rVSV-ZEBOV 相关的文献（医药）

2026-07-01·CLINICAL MICROBIOLOGY AND INFECTION

A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV)

Article

作者: Morrow, Matthew P ; Lemeille, Sylvain ; Siegrist, Claire-Anne ; Boehm-Bosmani, Cristina ; Eberhardt, Christiane ; Sharkhith, Hiba ; Vetter, Pauline ; Humeau, Laurent M ; Pignac-Kobinger, Judith ; Reuschel, Emma L ; Nepveu-Traversy, Marie-Edith ; Fontannaz, Paola ; Huttner, Angela ; Liebowitz, Dave ; Roth, Romain ; de La Vega, Marc-Antoine ; Gillespie, Elisabeth ; Sylvester, Albert J ; Orizu, Bonaventure ; Kobinger, Gary P ; Boyer, Jean ; Didierlaurent, Arnaud M

OBJECTIVES:

Nearly a million people have received the recombinant vesicular stomatitis virus-based vaccine expressing the surface glycoprotein of Ebola virus (rVSVΔG-ZEBOV-GP), whose immune durability is unknown. We evaluated the safety and immunogenicity of the DNA vaccine candidate INO-4201 in volunteers primed with the rVSVΔG-ZEBOV-GP vaccine.

METHODS:

This investigator-initiated phase Ib double-blind, placebo-controlled, single-centre trial randomly assigned healthy adults (≥18 years) primed with rVSVΔG-ZEBOV-GP to intradermal INO-4201 (1 mg) or placebo (4:1), both followed with electroporation. The coprimary outcome was incidence of adverse events at 14 days and geometric mean EBOV-GP-binding antibody titres (GMT) at 28 days (clinicaltrials.gov NCT04906629).

RESULTS:

Forty-six participants were enrolled. Median age was 52 years (interquartile range 44-57); 26 (57%) were male. Thirty-six participants received INO-4201 and 10 participants received placebo. No serious adverse events occurred. There was little reactogenicity. At 14 days, 20 of 36 (56%) vaccinees versus 5 of 10 (50%) placebo recipients (relative risk 1.11 [95% CI 0.56-2.20]) experienced adverse events. Peak T-cell responses were significantly increased in INO-4201 recipients (median percentage of CD4 cells producing interferon-gamma at postboost peak versus day 0: 0.09 [range 0.00-14.48] versus 0.00 [0.00-1.33], p 0.004). Filovirus Animal Non-Clinical Group-based EBOV-GP-binding titres were significantly higher after boosting for vaccinees at all time points (GMT at 4 weeks versus day 0: 3221.7 [95% CI 2629.8-3946.8] vs 704.3 [513.8-965.3]). Neutralizing antibody titres were also significantly higher after boosting for vaccinees at all time points measured (GMT at 4 weeks versus day 0: 21.3 [95% CI 13.8-32.7] versus 2.4 [1.5-3.9]).

CONCLUSIONS:

In adults primed with rVSVΔG-ZEBOV-GP, INO-4201 demonstrated favourable safety and significant immunogenicity.

2026-05-05·Microbiology Spectrum

Article

作者: Siegrist, Claire-Anne ; Novedrati, Maria ; Medaglini, Donata ; Sonnati, Chiara ; Eckerle, Isabella ; Santoro, Francesco ; Lucchesi, Simone ; Martinez-Murillo, Paola ; Montesi, Giorgio ; Alvarez, Catia

ABSTRACT:

The recombinant vesicular stomatitis virus–vectored Zaire Ebola virus glycoprotein (rVSVΔG-ZEBOV-GP) vaccine, while effective and well-tolerated, exhibits notable reactogenicity, manifesting in expected adverse events (AEs), such as fever, headache, and pain, along with rare, unexpected AEs, including skin lesions, cutaneous vasculitis, and transient arthritis. The presence or absence of AEs following rVSVΔG-ZEBOV-GP vaccination is associated with a specific innate plasma signature. This study aims to elucidate in vitro the tropism of the vaccine for different cell types derived from tissues previously reported to be involved in the unexpected AEs. Upon in vitro infection with rVSVΔG-ZEBOV-GP, various cell types, such as synoviocytes, fibroblasts, keratinocytes, and endothelial cells (except chondrocytes), demonstrate productive infection, which in dermal fibroblasts triggered the release of many innate plasma signature markers, including keratinocytes’ pro-inflammatory and proapoptotic cytokines such as OSM and TRAIL. Infected monocytes from buffy coats, activated by infection, produce most innate plasma signature markers. In co-culture, rVSVΔG-ZEBOV-GP-infected monocytes serve as a source to synoviocyte infection, resulting in distinct kinetics modulation in innate biomarkers (transcription and secretion) and upregulation of specific genes, such as NEDD8 and SIGLEC-1 , which have been associated with inflammatory arthritis in animal models. Altogether, our work, based on in vitro studies, provides insights into the possible mechanisms of rVSVΔG-ZEBOV-GP underlying the observed reactogenicity by showing tropism of the vaccine for off-target cells derived from AE-affected compartments (skin, joints, vessels). Furthermore, in vitro interaction with infected monocytes modulates the innate response of synoviocytes.

IMPORTANCE:

Our study expanded knowledge about the cellular tropism of rVSVΔG-ZEBOV-GP vaccine toward peripheral blood mononuclear cells and cell lines derived from tissues (skin, vessels, and joints) associated with unexpected AEs, as well as their possible contribution to the vaccine-induced innate response. Using in vitro infection and co-culture techniques, we showed that rVSVΔG-ZEBOV-GP-infected monocytes can transmit the virus to synoviocytes, and how infection affects human monocytes and synoviocytes at the protein and transcriptomic levels. Our findings provide insights into the in vitro off-target infection dynamics and innate immune response triggered by rVSVΔG-ZEBOV-GP vaccine. While these results may enhance understanding of rVSV-based vectors, in vivo relevance remains unclear, as does whether the effects come from the VSV backbone or Ebola GP. These findings support the evaluation of off-target effects of rVSV-based vaccine candidates, including those under development for hemorrhagic fever viruses, such as Marburg virus, Sudan virus, and Lassa virus, especially if similar AEs are observed.

2026-04-01·VACCINE

Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection

Article

作者: Marzi, Andrea ; Wagner, Sheridan B ; Malherbe, Delphine C ; Napier, Ethan G ; Messaoudi, Ilhem

Since the West African Ebola virus (EBOV) epidemic in 2014-2016, recurrent outbreaks of the EBOV-Makona variant have been driven by recrudescence and human-to-human transmission emphasizing the need for effective vaccination strategies. A live-attenuated recombinant vesicular stomatitis virus (VSV)-based vaccine expressing the EBOV-Kikwit variant glycoprotein (VSV-Kik) received FDA approval in December 2019 and provides complete, rapid protection against EBOV-Makona as early as 7 days post-vaccination (DPV). During the 2018-2020 Ebola outbreak, the VSV-Kik vaccine, known as ERVEBO, was administered to lower-risk individuals at a 5-fold dose reduction of the standard 2 × 10⁷ PFU to provide broader population protection. Identification of a protective lower dose providing rapid protection would ease supply burdens during future outbreaks and enhance vaccine coverage. We previously generated a VSV-based vaccine expressing the glycoprotein of the Makona variant (VSV-Mak) which provided complete protection against homologous challenge 28 DPV at as low as 1 × 10¹ PFU. However, the transcriptional responses engendered by VSV-Mak and VSV-Kik vaccines in the context of early EBOV-Makona challenge have not yet been evaluated. In the current study, we compared transcriptional responses following a low dose (1 × 10⁴ PFU) of lab-grade VSV-Mak or GMP-grade VSV-Kik and subsequent EBOV-Makona challenge 10 DPV. VSV-Kik provided complete protection against heterologous challenge and elicited rapid antiviral transcriptional changes followed by the activation of adaptive immunity. On the other hand, VSV-Mak only provided partial protection and induced minimal transcriptional response. These results highlight a glycoprotein-specific transcriptional response after vaccination despite the high EBOV variant homology.

129

项与 rVSV-ZEBOV 相关的新闻（医药）

2026-09-07

·医脉通

护士把医生打骨折？医院12次协调、派出所4次调解均无果，医院回应 | 医脉3分钟

今天的医疗圈发生了哪些与你有关的大事？更新、更全的医学动态 3分钟一网打尽 ******** 今日关键词：最新流感疫苗接种指南，骗保典型案例，锦旗藏刀伤医事件来源 | 医脉通作者 | 晚报君新闻60秒 ➤中疾控发布最新流感疫苗接种指南 @中国疾病预防控制中心近日，中国疾病预防控制中心发布《中国流感疫苗预防接种技术指南（2026—2027）》，明确建议所有6月龄及以上且无接种禁忌的人群接种流感疫苗。优先推荐医务人员、60岁及以上老年人、慢性病患者、养老机构等人群聚集场所脆弱人群及员工、6月龄及以上至5岁以下儿童、6月龄以下婴儿的家庭成员及看护人员、托幼/中小学/监管场所等重点场所人群、孕妇等8类重点人群接种。《指南》指出，本年度我国上市的三价流感疫苗包括三价灭活疫苗（IIV3）和三价减毒活疫苗（LAIV3）。 ➤6起骗保典型案例发布：涉案超千万，多人获刑 @最高人民检察院 9月4日，最高人民检察院官方微信发布消息，最高检、国家医保局联合发布6件医保骗保典型案例，紧盯医疗机构骗保、回流药套现、职业骗保人作案、虚构劳动关系骗取生育津贴等高发问题，涉案金额最高超千万元。其中不乏以免费住院、返现诱导参保人、借助互联网医院线上线下勾结套取基金等新型作案手段。多起案件中多名主犯获重判。两部门强调将坚持从严打击，强化行刑衔接、追赃挽损，推动医保领域综合治理。 ➤5岁女孩被医生标注“刁蛮”，涉事医生被立案调查 @央广网近日，广东湛江吴川市一家长反映，其5岁女儿因过敏到吴川市黄坡镇中心卫生院就医，当值医生拒绝看病。事后一周，家长发现孩子的电子病历“既往史”一栏被医生标注“刁蛮”二字，引发关注。 9月5日晚，吴川市卫生健康局接受记者采访时表示，经核查情况属实，吴川市卫生健康局联合相关部门已于9月5日赴黄坡镇开展调处，向患者家属通报了处置工作情况，家属充分认可，表示接受调查结果。同时有关部门对当事医生开展思想教育和纪律教育，其已深刻反思自身错误，并于当天下午向患者进行真诚道歉，双方达成和解。吴川市卫生健康局已对涉事医生予以警告、批评教育和立案调查，并约谈黄坡镇中心卫生院主要负责人，责令改正该院在处理医患纠纷问题上未主动担责的失职失责行为，进一步健全完善投诉管理机制，开展医德医风专项整治行动，全力构建良好和谐的医患关系，切实维护群众就医权益。 ➤男子被医院误诊胃癌切全胃，获赔22万 @经视直播武汉吴先生因腹痛就医，初查胃溃疡后，其妻找外院教授阅片，教授却怀疑是胃癌，家人隐瞒病情劝吴先生转院。此前组织活检报告显示未见癌细胞，但吴先生后来的主治医生仍建议手术切除其四分之三的胃，术中直接改为全胃切除。术后病理显示无任何癌细胞。术后吴先生留下严重消化后遗症，被评定为五级伤残。双方协商赔偿无果后诉至法院，经司法鉴定，法院判定医院承担六成责任，赔偿损失201083元，另赔20000元精神损害金。官方60秒 ➤“患者锦旗里藏刀刺伤医生”，警方通报 @贵阳市公安局南明分局 9月6日凌晨，贵州省贵阳市公安局南明分局发布警情通报称，9月4日9时许，贵州省中医药大学第二附属医院红岩院区发生一起刑事案件，致1人受伤。该局迅速出警，当场将犯罪嫌疑人胡某某控制。目前，伤者已送医救治，伤情稳定，现无生命危险。犯罪嫌疑人胡某某已被公安局依法刑事拘留，案件正在进一步侦办中。此前有媒体报道，多名网友反映贵州中医药大学第二附属医院红岩院区发生一起伤医事件。一名肠癌患者因不满治疗效果，将刀具藏在锦旗中带入医院，欲找老专家未果后，持刀刺向旁边科室的医生。受伤医生系该院肛肠科住院医师，因其腿脚不便，面对突发袭击时未能及时躲避。 ➤护士把医生打骨折？医院12次协调、派出所4次调解均无果，医院回应 @澎湃新闻 8月30日，有网友在问政湖南上留言称，其是嘉禾县人民医院的一名医生，于今年4月6日上班期间被殴打，致上颌骨额突骨折，住院接受手术治疗，事发当时已报警。但近5个月时间里，单位及派出所未对殴打者作出任何处理。嘉禾县人民医院9月3日回应称，该院疼痛门诊医师唐某、护士欧某两人在工作中产生矛盾，发生肢体冲突，致唐某鼻部被椅子碰伤，唐某向珠泉镇派出所报警，唐某经诊断为：上颌骨额突骨折。在伤者治疗期间以及康复出院后，医院先后组织3次调查，12次协调处理，派出所前后组织当事双方及医院代表进行了4次调解，但因当事双方在民事赔偿方面分歧较大始终未达成一致意见，遂未形成最终处理结果。嘉禾县人民医院还表示，医院将依据派出所及医院调查情况，根据当事双方的过错情节，依照医院内部管理制度，对涉事双方进行严肃追责与处理。国际60秒 ➤美国麻疹病例数创35年来新高，今年病例已逾3000例 @央视新闻当地时间9月4日，美国疾病控制与预防中心（CDC）表示，今年迄今为止，美国已确诊3134例麻疹病例，创下35年多来的年度最高纪录。CDC记录显示，今年已出现38起新的疫情暴发，而2025年为48起。今年因麻疹住院的病例为248例（占总病例的8%），相比之下，2025年共有244例住院和3例死亡。 ➤死亡3039例，病死率48.6%！一地疫情持续，一线医护开始接种疫苗 @新华社非洲疾病预防控制中心官员韦萨姆·曼库拉3日在线上记者会上说，刚果（金）本轮埃博拉疫情近期出现一些积极迹象，但新增病例数尚未形成持续下降趋势，目前仍不能断言疫情已得到控制。刚果（金）8月27日启动Ervebo疫苗接种工作，为医护人员等接种。截至9月1日，共有1124名医护人员和其他一线工作人员接种了该疫苗。刚果（金）卫生部3日发布的疫情数据显示，截至9月1日，该国累计报告埃博拉确诊病例6250例，其中死亡3039例，病死率为48.6%。责编｜Atai 封面图来源｜医脉通退休医务人员也可参与！“银龄医师”将助力县级医院提升 | 医脉政事儿仅仅7天，从发热、咳嗽到脓毒性休克：这场看似突然的病情“爆发”，问题到底出在哪里？丨医起推理吧医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「MedSeeker」「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。 ☟戳这里，更有料！

疫苗

2026-08-30

·微信

智健富康周刊

智健富康周刊 · 第16期 · 总第69期 Vol.16 🏥 智健富康周刊 2026年8月30日 · 8.23—8.30 · 💊 智健富康推送 ✅ 国产腔镜机器人完成2400公里超远距"力反馈"远程手术🔬 Cleveland Clinic基因疗法一次注射让脂蛋白(a)显著降低近一年💡 英国UCLH完成全球首例AI实时辅助脑外科手术🏥 长护险支付管理指导意见等养老政策"三连发" 让健康触手可及 · 每周日更新 📌 本期导读本期聚焦2026年8月23日至30日一周国内外医疗健康重磅动态。国内方面，东南大学宋爱国团队联合郑大一附院、新疆医科大学一附院，用搭载力感知的国产腔镜手术机器人完成2400公里超远距远程手术，填补国产腔镜机器人力交互空白；上海张江药谷创新药械密集落地，从腹主动脉支架到PNH、SLE、戈谢病多管线齐发；恒瑞、三生国健、康方、来凯等国产创新药接连获批或受理。养老领域，国家医保局长护险支付管理指导意见、市场监管总局陪同就医服务国标、工信部智能家居适老化标准"三连发"，地方实践同步提速。国际方面，英国UCLH完成全球首例AI实时辅助脑外科手术，Cleveland Clinic基因沉默与CRISPR疗法在降胆固醇上取得里程碑式数据，刚果（金）埃博拉疫情升级为该国史上最大规模，AI诊断在生物学年龄、头颈癌早筛、心肌病识别等方向多点突破。🌏 国内篇 🏷️ 国产智造 · 远程手术 01｜2400公里"手感"实时传递：国产腔镜机器人远程手术破壁东南大学宋爱国教授团队研发的力交互腔镜手术机器人，近日在郑州大学第一附属医院与新疆医科大学第一附属医院之间，完成跨越约2400公里的超远距远程手术：包括2例肾部分切除与1例前列腺癌根治。与常规远程手术仅传输"视觉画面"不同，该系统首次将操作端的"力反馈"实时同步至远端，主刀医生能"感知"组织硬度与牵拉阻力，使远程操作从"看得见"迈向"摸得着"。这标志着国产腔镜机器人在力感知这一核心技术上实现突破，填补了相关空白。新疆地域辽阔、优质外科资源相对稀缺，此类技术成熟后，患者有望在本地医院享受到千里之外顶尖专家的"亲手"手术，对优质医疗资源下沉边疆、应急医学救援与分级诊疗具有标志性意义。解读：力反馈是手术机器人的"灵魂"。达芬奇等进口系统长期垄断力感知核心技术；国产系统在"远程+力反馈"上的突破，意味着我们在高端手术装备上正从"跟跑"走向"并跑"乃至"领跑"。远程手术若要规模化，网络时延确定性、责任界定与应急断网预案等落地问题仍需逐一破解。 📖 来源：东南大学 · 郑大一附院 · 新疆医科大学一附院 · 2026-08 🏷️ 创新集群 · 上海张江 02｜张江药谷一周"多点开花"：从腹主动脉支架到PNH、SLE、戈谢病 ① 心脉医疗Aorfix腹主动脉支架落地澳门首例临床应用，为复杂腹主动脉瘤患者提供新的微创选择；② 阿斯利康瑞利珠单抗获国家药监局批准用于阵发性睡眠性血红蛋白尿症（PNH）；③ 宜明昂科IMM0306（CD47×CD20双靶点）治疗系统性红斑狼疮（SLE）获FDA批准Ib/II期临床研究；④ 北海康成即将启动戈芮宁用于儿童戈谢病的临床试验。一周之内，张江在高端植介入器械、补体靶向药、双抗、罕见病用药四大方向同步推进，覆盖从心血管到自身免疫、从常见病到罕见病的广泛谱系。解读：张江作为国家级生物医药集群，正从单一"研发聚集"升级为"研发—临床—出海/落地"的完整生态。PNH、SLE、戈谢病均为长期缺乏满意疗法的领域，多管线齐发直接惠及患者，也凸显本土创新从"仿创"向"首创"的结构性转身。 📖 来源：上海张江药谷 · 企业公告 · 2026-08 🏷️ 创新药 · 获批受理 03｜一周新药速览：恒瑞、三生国健、康方、来凯多款重磅进展 ① 恒瑞医药富马酸立康可泮胶囊（补体B因子抑制剂）8月20日获批，用于未接受过补体抑制剂治疗的PNH成人，累计研发投入约2.78亿元；② 三生国健安弗利奇塔单抗（抗IL-1β人源化单抗，益赛那®）8月20日获批，用于成人急性痛风性关节炎发作（对NSAIDs/秋水仙碱不耐受者），为国内第二款IL-1β药物。 ③ 康方生物依沃西单抗（PD-1/VEGF双抗，依达方®）联合化疗一线治疗晚期鳞状非小细胞肺癌获批，为其第3个肺癌适应症；④ 来凯医药LAE002（AKT强效抑制剂）联合氟维司群治疗HR+/HER2-、伴PIK3CA/AKT1/PTEN改变的乳腺癌，新药上市申请（NDA）获受理。解读：中国创新药正从"fast-follow"向"差异化首创"跃迁。补体、IL-1β、双抗、AKT等靶点的密集落地，显示本土药企在自身免疫、肿瘤、代谢领域的系统布局日趋成熟，国产创新正进入"批量兑现"阶段。 📖 来源：国家药监局 · 企业公告 · 2026-08 🏷️ 百强医院 · 临床首创 04｜百强医院一周：北大三院建细胞治疗"质量促进中心"，齐鲁首创双颈入路食管癌根治北京大学第三医院获批北京市细胞及其衍生物治疗新技术质量促进中心，将在细胞治疗（如CAR-T、干细胞等）的质量控制、技术规范与转化路径上发挥枢纽作用；山东大学齐鲁医院胸外科完成国内首例双颈入路充气式纵隔镜同步腹腔镜食管癌根治术，以微创方式减少创伤、加速康复。两家百强医院，一条线指向"新兴疗法的质量底座"，一条线指向"术式的微创进化"，折射出顶级医院"临床+转化"双轮驱动的新常态。解读：顶级医院正从"做临床"走向"定标准"。细胞治疗质量促进中心的设立，指向这一新兴疗法规模化前必须解决的安全与均一性问题；而术式微创新则持续提升患者获益。二者共同说明：百强医院的竞争维度，已从单台手术走向体系能力。 📖 来源：北大三院 · 齐鲁医院 · 2026-08 🏷️ 政策 · 养老保障 05｜养老政策"三连发"：长护险支付管理、陪同就医国标、适老化标准同日推进 ① 国家医保局印发《关于做好长期护理保险支付管理工作的指导意见》，规范长护险的支付范围、结算与基金管理，为失能老人长期照护提供制度保障；② 市场监管总局批准《社会化陪同就医服务基本要求》国家标准，将于11月1日实施，规范陪诊这一新兴业态；③ 工信部在国新办发布会上表示将加强智能家居、老年用品等领域标准供给，以标准牵引银发产业提质。三部门于8月26日从不同维度同步出手，勾勒出"资金（长护险）—服务（陪诊）—产品（适老家居）"的银发经济闭环。解读：长护险解决"钱从哪来"，陪诊国标解决"服务谁来做、怎么做"，适老化标准解决"产品靠不靠谱"。三者协同，正是对我国60岁以上人口约3.23亿、占比23%这一"健康老龄化"基本国情的系统性回应——政策正在从"兜底"走向"提质"。 📖 来源：国家医保局 · 市场监管总局 · 工信部 · 2026-08-26 🏷️ 地方实践 · 医养结合 06｜从海南到上海：地方医养结合"因地制宜"加速落地海南12部门启动"乐享银龄"七大行动，系统布局老年健康服务；山西运城16部门出台医养结合高质量发展举措，力争2030年底实现医养结合县域全覆盖；上海静安探索"五床联动"照护机制，打通居家、社区、机构与医疗床位衔接；内蒙古启动智能家居及适老化家居购新补贴，以消费端补贴撬动适老化改造。从海岛型省份到资源型城市、超大型城市与边疆地区，四种路径各有侧重，共同指向"医养结合最后一公里"的落地探索。解读：顶层政策需要地方"施工图"。海南的"七大行动"、运城的"县域全覆盖"、上海的"五床联动"、内蒙古的"补贴撬动"，分别代表了不同资源禀赋下的解题思路。医养结合没有标准答案，因地制宜才是关键。 📖 来源：各地政府 · 2026-08🌐 国际篇 · 全球前十医院 🌍 全球前十 · AI外科（英国） 07｜英国UCLH全球首例：AI实时"盯着"屏幕，辅助脑外科手术伦敦大学学院医院（UCLH）国家神经病学和神经外科医院完成全球首例AI实时辅助脑外科手术——经鼻腔内窥镜切除一例11毫米垂体瘤。AI系统在手术中同步读取内窥镜实时画面，自动高亮标注血管、神经与安全操作范围，并实时追踪器械位置。传统垂体瘤手术有25%—50%概率无法完整切除、0.5%—2%概率误伤大血管；该系统由数百台垂体瘤手术视频训练，获英国国家健康与护理研究所与谷歌资助，目前仍处临床试验阶段。解读：这并非"AI主刀"，而是"AI当副驾"——在术者视野内叠加风险热力图，把"看不见的危险"变成"看得见的提示"。相比完全自主手术，这种"人在回路"的实时辅助更易通过伦理与监管关卡，也最可能率先规模化落地。 📖 来源：UCLH · 2026-08-28 🌍 全球前十 · 基因治疗（美国） 08｜Cleveland Clinic里程碑：一次注射，脂蛋白(a)显著降低近一年克利夫兰医学中心（Cleveland Clinic）报告两项基因治疗突破：其一，首个人体长效基因沉默疗法单次注射后，使"坏胆固醇"脂蛋白(a)［Lp(a)］显著降低并维持近一年；其二，首个CRISPR基因编辑疗法人体试验显示，单次输注12个月后低密度脂蛋白（LDL）降低52.5%、甘油三酯降低47.8%，且安全性持续。 Lp(a)与LDL是心血管疾病的两大独立危险因素，过去长期缺乏有效药物手段。两项研究分别指向"沉默致病基因"与"编辑致病基因"两条技术路线。解读：心血管病长期靠"每天吃药"控制危险因素；基因编辑/基因沉默把范式扭转为"一次治疗、长期甚至终身获益"。若后续III期验证成功，这将是从"慢性病管理"迈向"一次性根治"的范式革命，对全球数亿心血管高危人群意义深远。 📖 来源：Cleveland Clinic · 2026-08-28 ⚠️ 全球公卫 · 疫情警报 09｜全球公卫警报：刚果（金）埃博拉成史上最大规模，FDA更新版新冠疫苗获批 ① 刚果（金）本轮埃博拉疫情截至8月21日死亡超2500人，为该国防史上最大规模（超过2018—2020年疫情），病原为Bundibugyo亚型，目前无专门疫苗与治疗；约160名医护感染、43人死亡，半年内超260次针对医护袭击。国际已批准从全球疫苗储备释放7万剂默沙东Ervebo疫苗。 ② 美国FDA于8月28日批准2026—2027更新版COVID-19疫苗，针对XFG变异株，主要面向老年与高危人群。解读：一边是资源匮乏地区的"旧"疫情失控，一边是发达国家的"新"疫苗迭代，两张图景共同说明：全球公共卫生仍极不均衡。埃博拉警示我们，疫苗可及性与医疗人员安全是疫情防控的"最后一公里"；而新冠年年更新，则提示呼吸道病毒监测与疫苗快速更新已成常态化能力。 📖 来源：WHO相关通报 · FDA · 2026-08 🌍 全球前十 · AI诊断（美国） 10｜AI诊断多点突破：生物学年龄、头颈癌血液早筛、心肌病识别 Mass General Brigham推出FaceAge工具，用一张照片预测"生物学年龄"，可作健康风险生物标志物；其HPV-DeepSeek超灵敏血液检测可预测头颈癌复发与生存。Mayo Clinic则开发AI模型，用常规超声视频识别肥厚型心肌病（发表于Circulation: Cardiovascular Imaging）；另以AI识别IL-6受体阻滞剂预防MOGAD复发等。从照片、血液到超声视频，AI正以低成本、无创的方式渗透多种疾病的早筛与风险分层。解读：这些看似不相干的突破，底层是同一趋势：用无创方式把高风险人群"筛"出来。对老龄化社会而言，早筛早诊的边际价值远高于晚期治疗——AI诊断的普惠潜力，正在于把顶级专家的"火眼金睛"批量复制到基层。 📖 来源：Mass General Brigham · Mayo Clinic · 2026-08 💊 FDA批准 · 新药速览 11｜FDA一周新药速览：胰腺癌、骨髓瘤、HIV、皮肌炎多线突破 ① daraxonrasib获FDA批准用于既往治疗过的转移性胰腺癌（RASolute 302），ESMO指南推荐其用于RAS G12突变转移性PDAC化疗后；② iberdomide（首个CELMoD）获FDA批准治疗复发/难治性多发性骨髓瘤。 ③ Bixlenvo（bictegravir+lenacapavir）获FDA批准为HIV-1单片方案；④ Lisraya（首个口服双TYK2/JAK1抑制剂）获FDA批准用于皮肌炎；⑤ Mounjaro（替尔泊肽）扩展适应症，用于2型糖尿病合并心血管风险者降低主要不良心血管事件（MACE）。解读：这一周FDA的"丰收"覆盖了从罕见突变胰腺癌到常见慢病（HIV、糖尿病）的多层需求。RAS这一"不可成药"靶点的突破尤为关键——约30%的胰腺癌携带RAS突变，daraxonrasib为这一长期绝望的人群打开了新窗。 📖 来源：FDA · ESMO · 2026-08📌 本期速览 # 主题来源关键词 1 2400km力反馈远程手术郑大一附院/新疆医科大远程手术·国产机器人 2 张江药谷多管线落地上海张江创新药械·集群 3 国内新药密集获批恒瑞/三生/康方/来凯创新药·获批受理 4 百强医院一周动态北大三院/齐鲁医院细胞治疗·食管癌 5 养老政策"三连发" 医保局/总局/工信部长护险·陪诊·适老 6 地方医养结合实践海南/山西/上海/内蒙古医养结合·县域 7 AI实时辅助脑外科手术 UCLH（英国） AI·神经外科 8 基因沉默/CRISPR降胆固醇 Cleveland Clinic（美国）基因治疗·心血管 9 埃博拉疫情+新冠疫苗刚果（金）/FDA 公卫·疫苗 10 AI诊断多点突破 MGB/Mayo（美国） AI·早筛 11 国际新药速览 FDA 胰腺癌·骨髓瘤·HIV 智健富康推送聚焦医疗新技术 · 守护健康每一步 2026年8月30日 · 第16期 · 总第69期智健富康推送 · 每周日更新

2026-08-28

·北京医学感染与传染研究

临床微生物学与感染 32卷 7-9期、7期增刊

Clinical Microbiology and Infection[Jour] AND 32[volume] AND 7[issue] 临床微生物学与感染 32卷 7期 https://www.sciencedirect.com/journal/clinical-microbiology-and-infection/vol/32/issue/7 Editorial Note（编者注） 1 Call for editor in virology 病毒学编辑征稿启事 J. Rodríguez-Baño Page 1035 Commentaries（述评） 2 US WHO withdrawal and clinical readiness 美国退出世卫组织与临床应对准备 Lukasz Szarpak, Michal Pruc, Beata Piskorska, Maciej Maslyk Pages 1036-1038 3 Reunion's bold bet against leptospirosis 留尼汪岛抗击钩端螺旋体病的大胆举措 Anissa Desmoulin, Xavier Deparis, Barbara Kuli, Loïc Raffray, Emilie Mosnier Pages 1039-1041 4 Reviving β-lactams for Mycobacterium abscessus: the emerging role of durlobactam β-内酰胺类抗生素重振活力治疗脓肿分枝杆菌：杜洛巴坦的新兴作用 Chengcheng Wang, Zhiyong Zong Pages 1042-1044 Editorials（社论） 5 A cutting-edge vaccine could address a gap in protection against Ebola virus disease 一种前沿疫苗有望填补埃博拉病毒病免疫保护的空白 Armand Sprecher, Sylvie Jonckheere, Michel Van Herp Pages 1045-1046 6 Widespread extended-spectrum β-lactamase–producing Enterobacterales colonization in healthy individuals in Burkina Faso: a hidden community reservoir 布基纳法索健康人群中广泛存在产超广谱β-内酰胺酶肠杆菌目细菌定植：一个隐匿的社区储库 Caroline Theunissen, Olivier Denis Pages 1047-1049 Theme Issue（主题专刊） Theme Issue Editorial（专题社论） 7 Microbiome science at a turning point: from descriptive ecology to clinical decision making in infectious diseases 微生物组学正处于转折点：从描述性生态学走向感染性疾病的临床决策 Silvia Corcione, Nicolas Benech, Ed Kuijper Pages 1050-1051 Theme Issue Reviews（专题综述） 8 Role of the gut microbiome in shaping drug response in immunocompromised hosts 肠道微生物组在免疫功能低下宿主药物应答中的作用 Semeh Bejaoui, Federica D'Amico, Silvia Turroni Pages 1052-1059 9 The role of the gut microbiome in multidrug-resistant organism colonization and infection 肠道微生物组在多重耐药菌定植与感染中的作用 Blair Merrick, Rebecca Cooper, Benjamin Davido, Simon D. Goldenberg Pages 1060-1066 10 Dynamics of the gut and lung microbiota in severe infections: from observational studies to therapeutic strategies 严重感染中肠道与肺部微生物群的动态变化：从观察性研究到治疗策略 Duveke P.E. de Gaay Fortman, Robert F.J. Kullberg, W. Joost Wiersinga, Bastiaan W. Haak Pages 1067-1074 11 Advanced computational analysis in metagenomic studies to support precision medicine 宏基因组研究中支持精准医学的高级计算分析 Gianmarco Piccinno, Francesco Asnicar Pages 1075-1080 12 How to set up and manage a microbiome research facility 如何建立和管理微生物组研究设施 Jannie G.E. Henderickx, Wiep Klaas Smits, Georg Zeller, Ed J. Kuijper Pages 1081-1086 Systematic Reviews（系统综述） 13 The impact of toll-like receptor polymorphisms on susceptibility to fungal infections: a systematic review of genetic and clinical data Toll样受体多态性对真菌感染易感性的影响：遗传与临床数据的系统综述 Martha Fabielle Pereira Staiger, Gleyce Hellen de Almeida Souza, James Venturini, Nalu Teixeira de Aguiar Peres, ... Luana Rossato Pages 1087-1095 14 Host blood biomarkers for the diagnosis of childhood tuberculosis disease: a systematic review and meta-analysis 用于儿童结核病诊断的宿主血液生物标志物：系统综述与荟萃分析 Michael Prodanuk, James W. King, Jessie Cunningham, Ian Kitai, ... Melissa Richard-Greenblatt Pages 1096-1106 Guidelines（指南） 15 Guiding principles for implementing ESCMID clinical practice guidelines 实施ESCMID临床实践指南的指导原则 Bianca Albers, Blin Nagavci, Oana Joean, Sarah Tschudin Sutter, ... Marcus Zervos Pages 1107-1114 Picture of a Microorganism（微生物图鉴） 16 A hard tick on the scalp visualized by polarized and ultraviolet dermoscopy 偏振光与紫外线皮肤镜下头皮上的硬蜱 Jia-Xu Li, Dan-Qiong Zheng, Yi-Ming Fan Pages 1115-1116 Original Articles（论著） 17 Genomic determinants of Bacillus cereus and outcomes of infection in preterm neonates: a multicentre retrospective study 蜡样芽孢杆菌的基因组决定因素及早产儿感染预后：一项多中心回顾性研究 Alicia Chevalier, Mariem Ben Khedher, Antoine Tran, Matilde Coin, ... Raymond Ruimy Pages 1117-1124 18 Faecal colonization with extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae in rural Burkina Faso 布基纳法索农村地区产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的粪便定植 Daniel Valia, Ibrahima Karama, Brecht Ingelbeen, Zakaria Garba, ... Hector Rodriguez-Villalobos Pages 1125-1134 19 Changes in nasal and throat microbiota composition during and after mupirocin and chlorhexidine decolonization treatment in asymptomatic methicillin-resistant Staphylococcus aureus carriers: a longitudinal observational study 无症状耐甲氧西林金黄色葡萄球菌携带者接受莫匹罗星与氯己定去定植治疗期间及之后鼻咽部微生物群组成的变化：一项纵向观察研究 Sofie Marie Edslev, Cindy M. Liu, Bobby Zhao Sheng Lo, Heidi Meiniche, ... Marc Stegger Pages 1135-1143 20 Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteraemia: external validation with decision curve analysis DENOVA评分预测粪肠球菌菌血症感染性心内膜炎的临床效用：基于决策曲线分析的外部验证 Benedetta Varisco, Daniele Piovani, Elena Rosselli Del Turco, Linda Bussini, ... Martina Spaziante Pages 1144-1151 21 Clinical validation of a new multi-Aspergillus species reverse transcriptase quantitative PCR: a diagnostic case-control study 新型多曲霉属逆转录酶定量PCR的临床验证：一项诊断性病例对照研究 Marion Benazra, Wicem Mallek, Théo Ghelfenstein-Ferreira, Aude Sturny-Leclère, ... Alexandre Alanio Pages 1152-1157 22 A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV) 一项关于埃博拉病毒DNA疫苗候选物INO-4201的Ib期、安慰剂对照、随机临床试验，该试验在健康、已接种rVSVΔG-ZEBOV-GP的初免志愿者中，以电穿孔作为加强接种（Boost-EBOV） Angela Huttner, Marc-Antoine de La Vega, Cristina Boehm-Bosmani, Jean Boyer, ... Gary P. Kobinger Pages 1158-1164 23 Burden of HIV and hepatitis B and C viruses in incoming Venezuelan migrants at the Colombian border: a laboratory-based cross-sectional study, 2021–2023 2021–2023年哥伦比亚边境入境委内瑞拉移民中HIV及乙型和丙型肝炎病毒的负担：一项基于实验室的横断面研究 Felix Lehmann, Ruth Aralí Martínez-Vega, Andres Moreira-Soto, Carlos Hernán Becerra-Mojica, ... Jan Felix Drexler Pages 1165-1170 24 Association between early SARS-CoV-2 viral rebound and post-COVID conditions among immunocompromised patients: cohort study 免疫功能低下患者中早期SARS-CoV-2病毒反弹与新冠后遗症的关联：队列研究 Guozhang Lin, Yuchen Wei, Carlos King Ho Wong, Xi Xiong, ... Ka Chun Chong Pages 1171-1178 Research Note（研究简讯） 25 From compliance to complexity: the impact of in vitro diagnostic regulation for clinical microbiology laboratories 从合规到复杂：体外诊断法规对临床微生物学实验室的影响 Sangeeta Gaja-Lachman, Mariëlle De Visser-Timmermans, Diana Langerak, Amber Jansma, Erlangga Yusuf Pages 1179-1182 Letters（读者来信） 26 Emerging extraintestinal Vibrio infections in Ireland from clinical and marine sources, 2020–2022 2020–2022年爱尔兰来自临床与海洋来源的新兴肠道外弧菌感染 Brigid Hooban, Seán Olann Whelan, Amy Burke, Mary Lucey, ... Georgios Miliotis Pages 1183-1186 27 Neisseria meningitidis MenY ST-1466 harbouring Neisseria gonorrhoeae 16S rRNA allele causing false-positive Aptima® gonococcal nucleic acid amplification test results 携带淋病奈瑟菌16S rRNA等位基因的脑膜炎奈瑟菌MenY ST-1466导致Aptima®淋球菌核酸扩增检测假阳性 Sebastiaan J. van Hal, Emma Goeman, Yvette Davidson, Frances Jenkins, ... Monica Lahra Pages 1187-1189 28 Nationwide emergence of cefotaxime-resistant Neisseria meningitidis via interspecies gene transfer from penA795-bearing Neisseria commensals in China 中国境内通过种间基因转移自携带penA795的奈瑟菌属共生菌而出现的全国性头孢噻肟耐药脑膜炎奈瑟菌 Youxing Shao, Xin Lan, Mingliang Chen, Minggui Wang, Qinglan Guo Pages 1190-1192 29 Carbapenemase-producing Klebsiella pneumoniae harbouring virulence-associated genes among war-affected children from the Gaza Strip 加沙地带受战争影响儿童中携带毒力相关基因的产碳青霉烯酶肺炎克雷伯菌 Andrés Pérez-López, Anju Sharma, Ruwa Mohamed, Clement K.M. Tsui, ... Mohammed Suleiman Pages 1193-1195 Corrigendum（勘误） 30 Corrigendum to “A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study” [Clin Microbiol Infect 28 (2) (2022) 298.e9–e15] 勘误："一种高致死率且鼻咽拭子RT-PCR检测灵敏度低的新型SARS-CoV-2变异株：一项观察性研究" [Clin Microbiol Infect 28 (2) (2022) 298.e9–e15] Pierre Fillâtre, Marie-José Dufour, Sylvie Behillil, Rémi Vatan, ... Nicolas Massart Page 1196 Clinical Microbiology and Infection[Jour] AND 32[volume] AND 7S[issue] 临床微生物学与感染 32卷 7期增刊 https://www.sciencedirect.com/journal/clinical-microbiology-and-infection/vol/32/issue/7/suppl/S The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the EUCAST Subcommittee 全基因组测序在细菌抗菌药物敏感性预测中的应用 —— 欧洲抗微生物药物敏感性试验委员会分委会 2025 年更新报告 The publication of this supplement has been sponsored by the Antibiotic Resistance and Pathogenicity of Bacterial Infections Research Group, Instituto de Investigaci\xF3n Sanitaria Illes Balears (IdISBa) 本增刊出版由巴利阿里群岛卫生研究所（IdISBa）细菌感染耐药与致病性研究组资助 The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the European Committee on Antimicrobial Susceptibility Testing Subcommittee 全基因组测序在细菌抗菌药物敏感性预测中的应用 —— 欧洲抗微生物药物敏感性试验委员会分委会 2025 年更新报告 Ørjan Samuelsen, Carla López-Causapé, Frank Møller Aarestrup, Valeria Bortolaia, ... Antonio Oliver Pages S1-S34 【abstract】（摘要） Scope: The 2017 European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee report on the role of whole genome sequencing (WGS) in antimicrobial susceptibility testing (AST) concluded that WGS antimicrobial susceptibility prediction (WGS-ASP) was not a sufffciently robust alternative to AST to guide clinical decision making at that stage and that more evidence was required [1]. Since then, the use of WGS, bioinformatic tools, machine learning (ML)/artiffcial intelligence (AI), databases, and prediction approaches has greatly expanded, along with an increased knowledge of resistance mechanisms and their contribution to antimicrobial susceptibility. In response, a new EUCAST ad hoc subcommittee was established in 2024 to review the literature, with the aim of assessing the current potential and limitations of WGS-ASP. 研究范围：2017年欧洲抗微生物药物敏感性试验委员会（EUCAST）分委会发布的全基因组测序（WGS）用于抗菌药物敏感性试验（AST）专项报告指出，彼时全基因组测序抗菌药物敏感性预测技术（WGS-ASP）稳定性不足，尚无法替代表型药敏试验指导临床诊疗决策，仍需积累更多研究证据[1]。此后，全基因组测序技术、生物信息学分析工具、机器学习/人工智能算法、耐药数据库及基因型预测模型得到广泛应用；同时，学界对抗菌药物耐药机制及其对药敏表型的影响认知持续深化。为此，EUCAST于2024年成立专项临时分委会，系统梳理现有文献，评估当前WGS-ASP技术的应用潜力与现存局限。 Methods: As in the previous report, the subcommittee reviewed the literature on a ‘by organism’ basis but expanded the list to also include enterococci, Haemophilus inffuenzae, and Bacteroides fragilis in addition to those already included in the ffrst version: Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, Neisseria gonorrhoeae, Staphylococcus aureus, Streptococcus pneumoniae, Clostridioides difffcile, and Mycobacterium tuberculosis. Additional sections were included to cover advances in metagenomics, other omics technologies and ML/AI. The full report was compiled and reviewed by all subcommittee members before public consultation in November 2025. 研究方法：与上一版报告一致，本分委会按照菌种分类开展文献综述；相较于初版，本次扩充菌种覆盖范围，除原有肠杆菌目、铜绿假单胞菌、鲍曼不动杆菌、淋病奈瑟菌、金黄色葡萄球菌、肺炎链球菌、艰难梭菌、结核分枝杆菌外，新增肠球菌、流感嗜血杆菌、脆弱拟杆菌。报告增设独立章节，系统阐述宏基因组学、其他组学技术及机器学习/人工智能领域的研究进展。完整报告经全体分委会成员编撰、内审后，于2025年11月面向公众征求意见。 Conclusions and Recommendations: Signiffcant progress has been achieved in WGS-ASP, with growing evidence supporting its ability to distinguish wild-type from non—wild-type isolates and, consequently, susceptible from resistant strains, particularly for M. tuberculosis and when clinical breakpoints align with the epidemiological cut-off (ECOFF). Despite these advances, important challenges remain before WGS-ASP can be adopted as a clinical decision-making tool. Addressing these gaps will require integrated phenotypic and genotypic surveillance to strengthen the evidence base for complex resistance mechanisms and newer antimicrobial agents, alongside comparative assessments that consider both ECOFF and clinical breakpoints. The analyses will require reference method phenotypic AST and highquality genomic data. It is critical to ensure that datasets reffect the target populations and encompass the full spectrum of antimicrobial susceptibility, while developing uniffed interpretation frameworks and harmonized bioinformatics tools to standardize outputs. Robust external quality assessment schemes will be essential for clinical validation, and emerging technologies such as AI and ML offer promising avenues to enhance predictive accuracy. Finally, improvements in cost and turnaround time, coupled with evaluations of setting-speciffc cost-effectiveness, will be key to enabling practical implementation of WGS-ASP. 结论与建议：WGS-ASP技术已取得长足进展，现有大量证据证实该技术可区分野生型菌株与非野生型菌株，进而判别敏感株与耐药株；针对结核分枝杆菌的检测优势尤为突出，且当临床折点与流行病学临界值（ECOFF）一致时检测效果更佳。尽管技术进步显著，若要将WGS-ASP作为临床常规决策工具，仍存在诸多亟待解决的难题。需联合开展表型-基因型一体化耐药监测，完善复杂耐药机制与新型抗菌药物相关研究证据；同时同步结合流行病学临界值与临床折点开展对比验证。相关研究需配套参比标准表型药敏试验与高质量基因组测序数据。数据集需贴合目标人群特征，覆盖全部药敏表型谱系；同时搭建统一判读体系、标准化生物信息学工具，实现检测结果规范化输出。完善、可靠的室间质评体系是该技术完成临床验证的核心保障；人工智能、机器学习等新兴技术可有效提升药敏预测准确度，具备良好应用前景。最后，降低检测成本、缩短报告周转时长，并结合不同医疗场景开展卫生经济学效益评估，是推动WGS-ASP落地临床实际应用的关键。 Ørjan Samuelsen, Clin Microbiol Infect 2026;32:S3 作者：厄尔扬·萨缪尔森发表期刊：《临床微生物学与感染》2026年；32卷：增刊3 Clinical Microbiology and Infection[Jour] AND 32[volume] AND 8[issue] 临床微生物学与感染 32卷 8期 https://www.sciencedirect.com/journal/clinical-microbiology-and-infection/vol/32/issue/8 Commentaries（述评） 1 Andes hantavirus outbreak on a cruise ship—an European Society of Clinical Microbiology and Infectious Disease Emerging Infections Subcommittee rapid assessment 邮轮安第斯汉坦病毒暴发——欧洲临床微生物与感染病学会新发感染分委会快速评估 Marta Mora-Rillo, Nitin Gupta, Effrossyni Gkrania-Klotsas, Jan Felix Drexler, ... Martin P. Grobusch Pages 1197-1201 2 Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo and Uganda: rapid assessment from the European Society of Clinical Microbiology and Infectious Diseases Emerging Infections Subcommittee 刚果民主共和国与乌干达本迪布焦埃博拉病毒暴发：欧洲临床微生物与感染病学会新发感染分委会快速评估 Nitin Gupta, Marta Mora-Rillo, Effrossyni Gkrania-Klotsas, Jan Felix Drexler, ... Sotirios Tsiodras Pages 1202-1207 3 Beyond sensitivity and specificity: designing outcome-driven evidence for infectious disease in vitro diagnostics 超越灵敏度与特异度：构建以临床结局为导向的感染病体外诊断循证依据 Benjamin Hommel Pages 1208-1210 4 Rethinking informed consent in phage therapy: why location and approach matter 重新审视噬菌体疗法知情同意：实施场景与沟通方式的关键价值 Ran Nir-Paz, Jean-Paul Pirnay, Tristan Ferry, Zuzanna Drulis-Kawa, ... Gina A. Suh Pages 1211-1215 5 Which trial do we need? The Selective Digestive Decontamination Herd Effects Estimation Trial (SHEET) study 我们需要何种临床试验？选择性消化道去污群体效应评估（SHEET）研究 James C. Hurley Pages 1216-1220 Editorial（社论） 6 Inputs of robust observational studies on encephalitis: the game will never be over 高质量观察性研究对脑炎诊疗的价值：探索永无止境 Pierre Fillâtre, Alexandra Mailles, Jean-Paul Stahl, Sylviane Defres, Pierre Tattevin Pages 1221-1223 Theme Issue（专刊） Theme Issue Editorial（专刊社论） 7 On silence and modesty 论医学研究中的审慎与谦逊 Katharina Last Page 1224 Theme Issue Reviews（专题综述） 8 Hybrid effectiveness-implementation studies in infection prevention and infectious diseases: a narrative review 感染防控领域效果-实施混合研究：叙述性综述 Lauren Clack, Marie-Therese Schultes, Bianca Albers, Aline Wolfensberger Pages 1225-1237 9 Anthropology of infectious disease emergence and epidemic control: a review 新发传染病与疫情防控的人类学视角：综述 Tamara Giles-Vernick, Jules Villa Pages 1238-1243 10 The human cost of resistance: ethical implications of coping with isolation for multidrug resistant organisms 耐药带来的人文代价：多重耐药菌隔离管理的伦理考量 Sibylle C. Mellinghoff, Alessandra A. Grossi, Claudia Recanatini, Leonie Breull-Wierschem, ... Norma Jung Pages 1244-1249 Narrative Reviews（叙述性综述） 11 Blood vessels at the crossroads: angiogenesis in the intersection of HIV and atherosclerosis 血管的交叉病理：HIV合并动脉粥样硬化中的血管新生机制 Pere Domingo, Paula Prieto, Marta Giralt, Didac Mauricio, Elvira Fernández Pages 1250-1259 12 Antifungal susceptibility testing across fungi: why MICs vary and methods diverge and what MIC can miss 广谱真菌药敏检测：最低抑菌浓度差异、检测方法分歧及检测盲区 Cornelia Lass-Flörl, Maximilian Lass, Jan Marco Kern, Silke Huber Pages 1260-1264 13 Antimicrobial stewardship during extracorporeal membrane oxygenation: challenges and new perspectives 体外膜肺氧合（ECMO）期间抗菌药物精细化管理：挑战与新进展 Salman Abdulaziz, Hanan Salah Alhajri, Miranda So, Salman Butt, ... Daniel Brodie Pages 1265-1272 Systematic Reviews（系统综述） 14 Nudging in MicroBiology laboratory Evaluation (NiMBLE): a systematic review and meta-analysis 微生物实验室干预引导策略（NiMBLE）：系统综述与荟萃分析 Bradley J. Langford, Elizabeth Leung, Esther Jeong, Kevin A. Brown, ... Larissa M. Matukas Pages 1273-1285 Position Paper（立场声明） 15 Language, trust, and the polio endgame: words matter in vaccine communication 语言、公众信任与脊髓灰质炎消除攻坚：疫苗科普沟通的措辞策略 Sotirios Tsiodras, Nitin Gupta, Thomas Hanscheid, Pikka Jokelainen, ... Martin P. Grobusch Pages 1286-1292 Picture of a Microorganism（微生物图鉴） 16 Plectosphaerella cucumerina fungal keratitis in an uncommon presentation 黄瓜隔孢菌所致非典型真菌性角膜炎 Lipeng Wang, Lihua Jiang, Shujun Liu, Maoli Yi Pages 1293-1294 Original Articles（论著） 17 Performance of an antigen test for detection of SARS-CoV-2, influenza, and respiratory syncytial virus—a prospective study 新冠病毒、流感病毒、呼吸道合胞病毒三联抗原检测效能：前瞻性研究 Karoline Berger, Siv-Hege Vang, Roy H.O. Bekkeseth, Anders Bredberg Pages 1295-1301 18 Risk of major structural birth defects following repeat mRNA COVID-19 vaccination in the first trimester: a population-based cohort study 孕早期重复接种mRNA新冠疫苗后重大结构性出生缺陷风险：基于人群的队列研究 Liang En Wee, Muhammad Ismail Bin Abdul Malek, Reen WL Ho, Jue Tao Lim, ... Kelvin B. Tan Pages 1302-1310 19 Persistence of late HIV diagnosis and poorer response to antiretrovirals: a comparison between migrants and native-born people with HIV in Spain HIV晚诊持续现状及抗逆转录病毒治疗应答不佳：西班牙移民与本土HIV感染者对比研究 Jose A. Perez-Molina, Miguel Suárez-Robles, María Belén Sánchez-López, Francisco Tejerina, ... M Ángeles Muñoz-Fernández Pages 1311-1321 20 Emergence of novel zoonotic and multidrug-resistant Streptococcus suis lineages 新型人兽共患病多重耐药猪链球菌谱系的出现 Jaime Brizuela, Gemma G.R. Murray, Parichart Boueroy, Andrew J. Balmer, ... Constance Schultsz Pages 1322-1330 21 Pharmacokinetic and pharmacodynamic evaluations of oral moxifloxacin for Enterococcus faecalis endocarditis 口服莫西沙星治疗粪肠球菌心内膜炎的药代动力学/药效学评价 Magnus Bock, Johan G.C. Van Hasselt, Kurt Fuursted, Nikolaj Ihlemann, ... Claus Moser Pages 1331-1337 22 Infectious encephalitis among adults: a prospective and population-based cohort study 成人感染性脑炎：前瞻性人群队列研究 Lærke Storgaard Duerlund, Lykke Larsen, Merete Storgaard, Helene Mens, ... Jacob Bodilsen Pages 1338-1346 23 Doxycycline in the treatment of outpatient mild community-acquired pneumonia: a propensity-matched retrospective cohort study 多西环素治疗门诊轻型社区获得性肺炎：倾向得分匹配回顾性队列研究 Genady Drozdinsky, Asaf Ness, Melanie Shahar, Shiri Kushnir, ... Noa Eliakim-Raz Pages 1347-1351 24 Rifapentine dosing for drug-susceptible tuberculosis: stage 1 of a seamless phase 2/3 randomized clinical trial 利福喷丁治疗药物敏感肺结核给药方案：无缝Ⅱ/Ⅲ期随机临床试验第一阶段研究 Yang Li, Lingyun Song, Zhen Feng, Xiaoqiang Zhang, ... Wenhong Zhang Pages 1352-1359 Research Notes（研究简报） 25 First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib 法匹拉韦、利巴韦林、艾替班特联合巴瑞替尼救治安第斯汉坦病毒心肺综合征首例报道 Miriam Estébanez, María Simón Sacristán, Tatiana Mata Forte, Anabel Negredo, ... Francisco Javier Areta Jimenez Pages 1360-1366 Letters（读者来信） 26 Re: ‘ESCMID clinical guidelines on the evaluation and management of a reported antibiotic allergy’ by Joean et al. 回应：Joean等人《ESCMID抗生素过敏评估与临床治疗指南》 Ignacio Martin-Loeches, Sean Keane Pages 1367-1368 27 ‘ESCMID clinical guidelines on the evaluation and management of a reported antibiotic allergy’—author’s reply 《ESCMID抗生素过敏评估与临床治疗指南》——作者回复 Oana Joean, Kevin Sermet, Blin Nagavci, Jonathan Sandoe, Mark de Boer Pages 1369-1370 28 Antibiotic allergy delabeling requires more than guidelines: the role of patient perspective 抗生素过敏去标签管理不能仅依靠指南：患者主观视角的重要作用 Neda Milevska-Kostova, Teske Schoffelen, Tessa Langeveld, Jeroen Schouten, Marlies E.J.L. Hulscher Pages 1371-1372 29 Re: ‘Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteraemia: external validation with decision curve analysis’ by Varisco et al. 回应：Varisco等人《DENOVA评分预测粪肠球菌菌血症并发感染性心内膜炎的临床价值：决策曲线分析外部验证》 Pierre Danneels, Floris Chabrun, Baptiste Clément, Xavier Duval, Vincent Dubée Pages 1373-1374 30 Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteraemia—Author's reply DENOVA评分预测粪肠球菌菌血症并发感染性心内膜炎的临床价值——作者回复 Benedetta Varisco, Linda Bussini, Davide Fiore Bavaro, Michele Bartoletti Pages 1375-1376 Clinical Microbiology and Infection[Jour] AND 32[volume] AND 9[issue] 临床微生物学与感染 32卷 9期 https://www.sciencedirect.com/journal/clinical-microbiology-and-infection/vol/32/issue/9 Commentaries（述评） 1 Advancing medicine, undermining life: a global health contradiction 推动医学进步却损害生命：一项全球卫生领域的矛盾 Edmond Puca, Francesca Rossi, Rima Moghnieh, Lukas Tometten, ... Ricardo Strauss Pages 1377‑1379 2 A European perspective on antibiotic use in viral respiratory infections: new paradigm integrating pathogens with host factors 病毒性呼吸道感染抗生素应用的欧洲观点：整合病原体与宿主因素的新模式 Şiran Keske, Virginie Prendki, Paraskevi C. Fragkou, Jordi Rello, the ESGREV and ESGIE Pages 1380‑1383 3 Antibiotic prophylaxis: a sharp tool that could be blunted easily 抗生素预防：一把易被钝化的利器 Marek Stefan, Marcela Krutova Pages 1384‑1387 3 Beyond the ward: the evolving roles of infectious disease specialists 走出病房：感染病专科医师角色的演变 Konstantinos Alexakis, Angela Ishak, Nikolaos Mazonakis, Constantinos Tsioutis, Nikolaos Spernovasilis Pages 1388‑1392 Editorial（社论） 4 From surveillance to participation: redefining respiratory virus epidemiology in the era of self‑testing 从监测到参与：自检时代下呼吸道病毒流行病学的重新定义 Markus Fally, Alexander G. Mathioudakis Pages 1393‑1395 5 Time to tap early: do not delay lumbar puncture in older adults 宜尽早实施：老年患者不应延迟腰椎穿刺 Marion Le Maréchal, Mathieu Vaillant Pages 1396‑1397 6 Can we improve on standard cefoxitin dosing for surgical prophylaxis? 外科预防用药中，我们能否优化头孢西丁标准给药方案？ Sheryl A. Zelenitsky Pages 1398‑1400 7 Diagnosing and managing unexpected donor bloodstream infection in organ transplantation 器官移植中供体不明原因血流感染的诊断与处理 Maddalena Giannella, Matteo Rinaldi Pages 1401‑1403 Narrative Reviews（叙述性综述） 8 Nipah virus in South Asia: from emergence to enduring preparedness' challenges 南亚尼帕病毒：从病毒出现到持续防控准备面临的挑战 Nitin Gupta, Effrossyni Gkrania‑Klotsas, Jan Felix Drexler, Sayantan Banerjee, ... Sotirios Tsiodras Pages 1404‑1411 9 Emerging mycoses: a neglected area of concern for global health 新发真菌病：全球卫生被忽视的关注点 Aleksandra Barac, Oliver A. Cornely, José Ramón Paño‑Pardo, Nitin Gupta, ... Martin P. Grobusch Pages 1412‑1417 10 New antifungals for the treatment of invasive mould disease 用于侵袭性霉菌病治疗的新型抗真菌药物 Nancy N. Vuong, David R. McClung, Samuel L. Aitken, Caitlin R. Rausch Pages 1418‑1424 11 Questions and issues of nonventilated hospital‑acquired pneumonia: an opinion document 非机械通气医院获得性肺炎的若干问题：一份专家意见文件 Marina Fayos, Almudena Burillo, Alicia Galar, Ana Álvarez Uría, ... Emilio Bouza Pages 1425‑1434 Systematic Reviews（系统综述） 12 Andes virus–associated cardiopulmonary syndrome: diagnostic approaches, clinical management, and evidence gaps—a scoping review 安第斯病毒相关心肺综合征：诊断手段、临床处置与证据缺口——范围综述 Federico Fama, Francesco Molà, Alberto Rizzo, Lucia Galli, ... Marta Colaneri Pages 1435‑1447 Position Paper（立场文件） 13 Position statement: integrating planetary health into infection prevention and control in healthcare settings—towards a balanced and evidence‑based approach 立场声明：将地球健康理念融入医疗机构感染预防与控制——构建均衡的循证实践路径 Ermira Tartari, Emine Alp Meşe, Andre N.H. Bulabula, Stephanie J. Dancer, ... Walter Zingg Pages 1448‑1462 Picture of a Microorganism（微生物图鉴） 14 Lumbar‑sacral giant sparganosis presenting as an intradural mass 表现为硬脊膜内占位的腰骶部巨大裂头蚴病 Jiarui Chen, Xinli Zhan, Chengqian Huang, Mingbo Wang, ... Chong Liu Pages 1463‑1464 Original Articles（原创论著） 15 Performance of a rapid, visual fingerstick serology self‑test for Helicobacter pylori detection and typing: a prospective multicentre diagnostic accuracy study 幽门螺杆菌检测及分型的指尖采血可视化血清学快速自检试剂盒效能：一项前瞻性多中心诊断准确性研究 Jing Chen, Tingting Wang, Song Liu, Jing Xiang, ... Changjiang Hu Pages 1465‑1471 16 Diagnostic accuracy and potential resource savings of pooled sputum testing with Xpert MTB/RIF Ultra for tuberculosis among adults in Vietnam: a cross‑sectional study 越南成人肺结核采用Xpert MTB/RIF Ultra混合痰液检测的诊断效能与潜在医疗资源节约：一项横断面研究 Han Thi Nguyen, Andrew James Codlin, Luan Nguyen Quang Vo, Nga Thi Thuy Nguyen, ... Tom Wingfield Pages 1472‑1479 17 Self‑testing for five respiratory viruses in adults ≥50 years of age in Germany for longitudinal monitoring of community‑acquired acute respiratory infections 德国≥50岁成人5种呼吸道病毒自检用于社区获得性急性呼吸道感染的纵向监测 Julia A. Nacov, Jon Salmanton‑García, Julia Jakobs, Miranda Anggitakirana, ... Oliver A. Cornely Pages 1480‑1486 18 Blinded two‑year longitudinal evaluation of SARS‑CoV‑2 antigenemia in long COVID 长新冠患者新冠病毒抗原血症为期两年的盲法纵向评估 Lourdes Mateu, Louise L. Hansen, Joao Pedro Carmezim, Cora Loste, ... Marta Massanella Pages 1487‑1494 19 Early vs late diagnosis in infectious encephalitis: a population‑based cohort study 感染性脑炎早期与晚期诊断对比：一项基于人群的队列研究 Lærke Storgaard Duerlund, Lykke Larsen, Merete Storgaard, Helene Mens, ... Jacob Bodilsen Pages 1495‑1502 20 Target‑controlled infusion vs. standard dosing of cefoxitin for surgical prophylaxis in colorectal surgery: a randomized clinical trial 结直肠外科手术预防感染：头孢西丁靶控输注与标准给药方案对比的随机临床试验 Jong Lyul Lee, Ha‑Jung Kim, Kyung Mi Kim, Jung‑Min Yi, ... In Ja Park Pages 1503‑1509 21 Impact of generic market entry on the consumption of last‑resort antibiotics in six European countries 仿制药上市对6个欧洲国家终极抗生素使用量的影响 Caroline Schweizer, Sebastian Weis, Evelina Tacconelli, Stephan Harbarth, ... Miriam Kesselmeier Pages 1510‑1516 22 Association between unrecognized donor bloodstream infection and outcomes in solid organ transplant recipients: a prospective observational cohort study 未被发现的供体血流感染与实体器官移植受者预后的关联：一项前瞻性观察队列研究 Andrea Cona, Caterina Curatolo, Paola Giordani, Flavia D'Andrea, ... Alessandra Mularoni Pages 1517‑1525 Research Note（研究简报） 23 Multicentre validation of EUCAST disk diffusion for frequently encountered anaerobic bacteria (excluding Cutibacterium acnes) in clinical microbiology laboratories in the Netherlands 荷兰临床微生物实验室针对常见厌氧菌（痤疮棒状杆菌除外）EUCAST纸片扩散法的多中心验证 Erlangga Yusuf, Wouter van den Bijlaardt, Helke van Dessel, Thomas Dierikx, ... Alida CM. Veloo Pages 1526‑1530 24 Ceftazidime‑avibactam‑resistant Klebsiella pneumoniae driven by multiple β‑lactamase mutations: a hospital outbreak report 多种β‑内酰胺酶突变介导的耐头孢他啶‑阿维巴坦肺炎克雷伯菌：一起医院暴发报告 Weiwei Yang, Chengkang Tang, Qingyu Shi, Hongjian Ou, ... Fupin Hu Pages 1531‑1535 Letters（读者来信） 25 Re: ‘Meropenem and fosfomycin against Klebsiella pneumoniae’ by Wicha et al. 对Wicha等人《美罗培南联合磷霉素抗肺炎克雷伯菌》一文的回复 Guofu Mao, Haizhen Lan Pages 1536‑1537 26 Meropenem and fosfomycin against Klebsiella pneumoniae: author‘s response 《美罗培南联合磷霉素抗肺炎克雷伯菌》：作者回复 Aneeq Farooq, Miklas Martens, Marie L.G. Attwood, Patrice Nordmann, ... Sebastian G. Wicha Pages 1538‑1539 27 Re: ‘Invasive fungal infections after CD19 chimeric antigen receptor‑T‑cell therapy for B‑cell lymphoma: a lymphoma study association study from the DESCAR‑T registry’ by Bouvier et al. 对Bouvier等人《B细胞淋巴瘤CD19嵌合抗原受体T细胞治疗后侵袭性真菌感染：DESCAR‑T登记库淋巴瘤研究联盟研究》一文的回复 Jice Wang Pages 1540‑1541 28 Invasive fungal infections after cluster of differentiation (CD19) chimeric antigen receptor (CAR) T‑cell therapy for B‑cell lymphoma: author’s response B细胞淋巴瘤CD19嵌合抗原受体T细胞治疗后侵袭性真菌感染：作者回复 Amélie Bouvier, François Lemonnier, Giovanna Melica Pages 1542‑1543 29 Tackling clinical research fragmentation in public health emergencies in Europe 应对欧洲突发公共卫生事件下临床研究碎片化问题 Evelyn Depoortere, Corinna Hartung, Teresa Chavarria Gimenez, Patricia Urbán, Cornelius Schmaltz Pages 1544‑1545 30 Delayed intestinal adenovirus response to intravenous brincidofovir in paediatric allogeneic stem cell transplant recipients displaying rapid clearance of the virus from peripheral blood 儿童异基因干细胞移植受者外周血腺病毒快速清除，但肠道腺病毒对静脉布林西多福韦应答延迟 Chantal Lucini, Sandra Preuner, Lisa Grösslinger, Nkechi Azie, Thomas Lion Pages 1546‑1548

100 项与 rVSV-ZEBOV 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	rVSV-ZEBOV	J07BX	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
埃博拉病毒性疾病	欧盟	Merck Sharp & Dohme BV	2019-11-11
埃博拉病毒性疾病	冰岛	Merck Sharp & Dohme BV	2019-11-11
埃博拉病毒性疾病	列支敦士登	Merck Sharp & Dohme BV	2019-11-11
埃博拉病毒性疾病	挪威	Merck Sharp & Dohme BV	2019-11-11
埃博拉病毒性疾病	英国	Merck Sharp & Dohme (UK) Ltd.	2019-11-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02788227 (CTgov)	临床2期	-	248	rVSV∆G-ZEBOV-GP vaccine (V920) (Post Month 18: Boosted Group)	壓齋窪繭選憲網廠繭觸(範襯範獵簾繭築觸襯鹹) = 壓願衊鏇觸鏇選窪窪鬱製襯襯膚顧積獵顧艱鏇 (製襯衊憲鹹膚遞襯製夢, 醖淵蓋蓋膚願簾鬱範廠 ~ 壓鹽夢齋鹹憲憲築醖廠) 更多	-	2026-06-17
				rVSV∆G-ZEBOV-GP vaccine (V920) vaccine (Post Month 18: Non-boosted Group)	壓齋窪繭選憲網廠繭觸(範襯範獵簾繭築觸襯鹹) = 襯鑰夢選顧選繭淵觸壓製襯襯膚顧積獵顧艱鏇 (製襯衊憲鹹膚遞襯製夢, 範鏇觸遞廠遞餘選顧構 ~ 遞構膚衊構簾齋鹽襯範) 更多
NCT02876328 (Pubmed \| Emerg Microbes Infect)	临床2期	埃博拉病毒性疾病	1,500	rVSVΔG-ZEBOV-GP	範淵願糧選鑰壓醖簾憲(襯膚選簾簾範襯選鹹簾) = 窪鏇製築築觸壓製鹹獵鬱醖膚夢窪膚製衊觸製 (醖築鹹鏇遞鬱淵蓋選襯 ) 更多	积极	2025-12-31
				Ad26.ZEBOVMVA-BN-Filo + Ad26.ZEBOVMVA-BN-Filo	廠顧顧選蓋艱蓋蓋願壓(選餘膚鏇餘夢壓糧遞顧) = 繭選繭憲齋襯製鹹鬱淵糧築齋淵鏇蓋鏇齋積衊 (製鬱範獵齋糧選鹹鹽製, 2.58 ~ 3.69) 更多
NCT02876328 (Pubmed \| Clin Infect Dis)	临床2期	埃博拉病毒性疾病	-	rVSVΔG-ZEBOV-GP vaccine (1 dose)	齋網廠遞鹽積齋觸鏇壓(膚蓋襯顧齋簾膚繭壓願) = 獵窪餘壓鏇壓壓鏇膚淵醖淵衊餘壓構製製選壓 (積夢觸網鏇齋網廠淵夢 )	-	2024-04-10
NCT02876328 (PREVAC, Pubmed \| N Engl J Med)	临床2期	埃博拉病毒性疾病	4,789	Ad26.ZEBOVMVA-BN-Filo (Ad26.ZEBOV followed by MVA-BN-Filo)	襯鏇衊鹹糧鏇願遞襯鹹(網糧選鹽鑰襯醖膚願鏇) = 糧鬱繭積鹹夢齋餘觸衊廠廠觸衊壓廠糧夢顧遞 (製艱選積築範築鏇窪簾, 401)	积极	2022-12-14
				Vaccines (rVSVΔG-ZEBOV-GP followed by placebo)	襯鏇衊鹹糧鏇願遞襯鹹(網糧選鹽鑰襯醖膚願鏇) = 選艱顧網糧蓋遞鏇鏇鑰廠廠觸衊壓廠糧夢顧遞 (製艱選積築範築鏇窪簾, 992)
NCT02378753 (STRIVE, Pubmed \| Emerg Infect Dis)	临床2/3期	怀孕	84	rVSVΔ-ZEBOV-GP Ebola Vaccine (Immediate vaccinated women)	憲製鑰網顧製製淵鏇遞(簾襯憲鹹餘廠襯簾鹹艱) = 願遞膚鹹願鹹網衊憲製襯淵艱製顧繭餘鏇憲夢 (壓壓壓繭簾鏇糧選鹹願 )	-	2020-03-17
				rVSVΔ-ZEBOV-GP Ebola Vaccine (Unvaccinated women)	憲製鑰網顧製製淵鏇遞(簾襯憲鹹餘廠襯簾鹹艱) = 壓網鹹衊壓餘膚獵顧鏇襯淵艱製顧繭餘鏇憲夢 (壓壓壓繭簾鏇糧選鹹願 )
NCT02269423 (V920-001, CTgov)	临床1期	埃博拉病毒性疾病	39	Placebo+V920 (3x10^6 Plaque-forming Units (Pfu) Vaccine Cohort)	艱憲衊艱艱繭遞鏇憲醖 = 鹽廠顧淵製鹹鑰構窪範襯鏇膚憲糧襯鏇顧繭遞 (蓋築網艱築範憲遞鏇選, 餘衊糧膚壓鹹憲築壓艱 ~ 遞積蓋夢築鹽糧鬱網鹹) 更多	-	2019-10-23
				Placebo+V920 (2x10^7 Pfu Vaccine Cohort)	艱憲衊艱艱繭遞鏇憲醖 = 鬱鏇憲簾襯鑰鏇壓遞醖襯鏇膚憲糧襯鏇顧繭遞 (蓋築網艱築範憲遞鏇選, 齋衊憲願鑰鹽製糧齋製 ~ 製網遞範鹹糧選憲顧獵) 更多
NCT02503202 (Pubmed \| J Infect Dis)	临床3期	-	1,197	rVSVΔG-ZEBOV-GP Vaccine (rVSVΔG-ZEBOV-GP (2 × 107 pfu))	選獵衊蓋顧鬱憲簾製鑰(範鹹繭醖鹽選範鏇觸範) = 鏇遞鑰遞築築網窪製簾鹽糧齋廠築獵衊齋衊鹹 (糧窪獵築顧淵蓋遞積壓 )	-	2019-08-30
				rVSVΔG-ZEBOV-GP Vaccine (high-dose 1 × 108 pfu)	選獵衊蓋顧鬱憲簾製鑰(範鹹繭醖鹽選範鏇觸範) = 築繭醖鹽獵構艱願繭鏇鹽糧齋廠築獵衊齋衊鹹 (糧窪獵築顧淵蓋遞積壓 )
NCT02280408 (V920-002, CTgov)	临床1期	埃博拉病毒性疾病	39	V920 (3x10^6 Plaque-forming Units (Pfu) Vaccine Cohort)	淵繭艱觸觸醖齋範憲鹹 = 醖積獵積網鹹製憲鹹簾醖構鬱獵糧淵鹽鏇觸糧 (鹽糧繭積範網願構醖網, 廠壓顧鏇廠艱簾簾觸鹽 ~ 廠築艱鬱壓鏇簾憲鏇餘) 更多	-	2019-07-12
				V920 (2x10^7 Pfu Vaccine Cohort)	淵繭艱觸觸醖齋範憲鹹 = 壓製齋願餘鏇艱製鏇夢醖構鬱獵糧淵鹽鏇觸糧 (鹽糧繭積範網願構醖網, 遞廠淵觸積鑰憲鏇願壓 ~ 鹽獵顧選鏇齋艱選鏇鏇) 更多
NCT02503202 (V920-012, CTgov)	临床3期	埃博拉病毒性疾病	1,197	V920 Consistency Lot A (V920 Consistency Lot A)	糧鬱餘齋鬱遞夢獵範醖(觸膚糧構積獵製窪繭網) = 夢襯鑰構願網鏇構餘鹽繭簾選膚鹽積廠網艱淵 (鏇範醖壓築鏇遞窪製廠, 憲餘網簾醖淵淵選顧範 ~ 淵蓋鏇衊鏇選膚壓艱製) 更多	-	2018-10-12
				V920 Consistency Lot B (V920 Consistency Lot B)	糧鬱餘齋鬱遞夢獵範醖(觸膚糧構積獵製窪繭網) = 顧艱淵遞範獵窪鏇鬱願繭簾選膚鹽積廠網艱淵 (鏇範醖壓築鏇遞窪製廠, 糧鹽餘繭醖壓壓鏇願餘 ~ 網餘簾積憲築簾鹽築壓) 更多
NCT02378753 (STRIVE, CTgov)	临床2/3期	埃博拉病毒性疾病	8,651	rVSVΔG-ZEBOV (rVSVΔG-ZEBOV (Immediate Vaccination))	衊獵簾艱構觸衊獵範膚 = 衊壓蓋網淵蓋醖願艱構衊觸積鹽廠鬱願積壓願 (願網糧憲蓋壓鬱糧鏇淵, 遞壓鹽淵廠鏇窪製鹽積 ~ 壓鹹範壓觸餘遞壓窪遞) 更多	-	2018-04-05
				rVSVΔG-ZEBOV (rVSVΔG-ZEBOV (Deferred Vaccination))	衊獵簾艱構觸衊獵範膚 = 醖鏇鏇糧襯遞蓋壓醖蓋衊觸積鹽廠鬱願積壓願 (願網糧憲蓋壓鬱糧鏇淵, 選選遞製觸鹹繭遞製鹽 ~ 壓鏇糧齋繭糧製艱壓鑰) 更多